サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1454882

夜間頻尿の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 適応症別、薬剤タイプ別、流通チャネル別、地域別

Nocturia Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 192 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
夜間頻尿の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 適応症別、薬剤タイプ別、流通チャネル別、地域別
出版日: 2024年03月11日
発行: Fairfield Market Research
ページ情報: 英文 192 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の夜間頻尿市場について調査し、市場の概要とともに、適応症別、薬剤タイプ別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナ・ロシア紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の夜間頻尿市場の見通し、2018年～2031年

  • 世界の夜間頻尿市場の見通し、適応症別、金額（10億米ドル）、2018年～2031年
  • 世界の夜間頻尿市場の見通し、薬剤タイプ別、金額（10億米ドル）、2018年～2031年
  • 世界の夜間頻尿市場の見通し、流通チャネル別、金額（10億米ドル）、2018年～2031年
  • 世界の夜間頻尿市場の見通し、地域別、金額（10億米ドル）、2018年～2031年

第4章 北米の夜間頻尿市場の見通し、2018年～2031年

第5章 欧州の夜間頻尿市場の見通し、2018年～2031年

第6章 アジア太平洋の夜間頻尿市場の見通し、2018年～2031年

第7章 ラテンアメリカの夜間頻尿市場の見通し、2018年～2031年

第8章 中東・アフリカの夜間頻尿市場の見通し、2018年～2031年

第9章 競合情勢

  • 適応症vs流通チャネルヒートマップ
  • メーカーと流通チャネルのヒートマップ
  • 企業市場シェア分析、2023年
  • 競合ダッシュボード
  • 企業プロファイル
    • Allergan, Inc.
    • Urigen Pharmaceuticals
    • Ferring Pharmaceuticals
    • Glenmark Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd.
    • AA Pharma Inc.
    • Avadel Pharmaceuticals plc

第10章 付録

目次

Fairfield Market Research a leading provider of market research reports, has released a comprehensive analysis of the global nocturia market spanning the period 2024-2031. The report aims to provide industry stakeholders with valuable updates on market trends and opportunities within the global landscape.

Rising Disease Prevalence Fuels Market Growth

The primary objective of the report is to shed light on developments in the Nocturia market that are reshaping businesses worldwide. Factors such as the increasing prevalence of cancer, diabetes, and cardiovascular diseases on a global scale have significantly contributed to the market's revenue growth. With a substantial portion of the population affected by these ailments, there is a growing demand for treatments targeting nocturia symptoms.

Driving Forces and Market Opportunities

The report highlights the factors expected to drive revenue growth in the global nocturia market, including greater access to manufacturing infrastructure, increased utilization of Contract Manufacturing Organizations (CMOs), and advancements in drug delivery systems. However, it also acknowledges challenges such as high operational costs and competition from low-cost manufacturers, which could potentially hinder market expansion.

Market Segmentation and Forecast

Fairfield Market Research analysis explores the global nocturia market performance, categorizing revenue contributions by different drug types. Among them, Desmopressin is anticipated to maintain its market leadership, with a projected growth rate throughout the forecast period. The Desmopressin segment's valuation, recorded in the past, is expected to see significant growth by the end of the assessment period.

Competitive Analysis

In the competitive assessment section, the report provides a detailed analysis of key market players, offering insights into their long-term and short-term strategies. Major manufacturing companies such as Allergan, Inc., Urigen Pharmaceuticals, Ferring Pharmaceuticals, Glenmark Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., AA Pharma Inc., and Avadel Pharmaceuticals plc are profiled, highlighting their product offerings and recent developments in the nocturia market.

Emphasis on Decision-Making Insights

The report includes impact analyses of key trends, drivers, challenges, and opportunities to equip clients with actionable information for strategic decision-making. Additionally, it features a competitive landscape with a dashboard view, enabling stakeholders to discern key differentiators among competitor firms.

Global Nocturia Market: Segmentation

Market segmentation by indication

  • Mixed nocturia
  • Low nocturnal bladder capacity
  • Nocturnal polyuria
  • Global polyuria

Market segmentation by drug type

  • Anticholinergic drugs
  • Desmopressin
  • Antibiotics
  • Antispasmodic
  • Others

Market segmentation by distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Market Segmentation by region

  • North America
  • Latin America
  • Europe
  • Asia Pacific excluding Japan
  • Japan
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Nocturia Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Nocturia Market Outlook, 2018 - 2031

  • 3.1. Global Nocturia Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Mixed nocturia
      • 3.1.1.2. Low nocturnal bladder capacity
      • 3.1.1.3. Nocturnal polyuria
      • 3.1.1.4. Global polyuria
  • 3.2. Global Nocturia Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Anticholinergic drugs
      • 3.2.1.2. Desmopressin
      • 3.2.1.3. Antispasmodic
      • 3.2.1.4. Others
  • 3.3. Global Nocturia Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospital Pharmacies
      • 3.3.1.2. Retail Pharmacies
      • 3.3.1.3. Drug Stores
      • 3.3.1.4. Online Pharmacies
  • 3.4. Global Nocturia Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Nocturia Market Outlook, 2018 - 2031

  • 4.1. North America Nocturia Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Mixed nocturia
      • 4.1.1.2. Low nocturnal bladder capacity
      • 4.1.1.3. Nocturnal polyuria
      • 4.1.1.4. Global polyuria
  • 4.2. North America Nocturia Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Anticholinergic drugs
      • 4.2.1.2. Desmopressin
      • 4.2.1.3. Antispasmodic
      • 4.2.1.4. Others
  • 4.3. North America Nocturia Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospital Pharmacies
      • 4.3.1.2. Retail Pharmacies
      • 4.3.1.3. Drug Stores
      • 4.3.1.4. Online Pharmacies
  • 4.4. North America Nocturia Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Nocturia Market Outlook, 2018 - 2031

  • 5.1. Europe Nocturia Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Mixed nocturia
      • 5.1.1.2. Low nocturnal bladder capacity
      • 5.1.1.3. Nocturnal polyuria
      • 5.1.1.4. Global polyuria
  • 5.2. Europe Nocturia Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Anticholinergic drugs
      • 5.2.1.2. Desmopressin
      • 5.2.1.3. Antispasmodic
      • 5.2.1.4. Others
  • 5.3. Europe Nocturia Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospital Pharmacies
      • 5.3.1.2. Retail Pharmacies
      • 5.3.1.3. Drug Stores
      • 5.3.1.4. Online Pharmacies
  • 5.4. Europe Nocturia Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Nocturia Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Nocturia Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Mixed nocturia
      • 6.1.1.2. Low nocturnal bladder capacity
      • 6.1.1.3. Nocturnal polyuria
      • 6.1.1.4. Global polyuria
  • 6.2. Asia Pacific Nocturia Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Anticholinergic drugs
      • 6.2.1.2. Desmopressin
      • 6.2.1.3. Antispasmodic
      • 6.2.1.4. Others
  • 6.3. Asia Pacific Nocturia Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospital Pharmacies
      • 6.3.1.2. Retail Pharmacies
      • 6.3.1.3. Drug Stores
      • 6.3.1.4. Online Pharmacies
  • 6.4. Asia Pacific Nocturia Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Nocturia Market Outlook, 2018 - 2031

  • 7.1. Latin America Nocturia Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Mixed nocturia
      • 7.1.1.2. Low nocturnal bladder capacity
      • 7.1.1.3. Nocturnal polyuria
      • 7.1.1.4. Global polyuria
  • 7.2. Latin America Nocturia Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Anticholinergic drugs
      • 7.2.1.2. Desmopressin
      • 7.2.1.3. Antispasmodic
      • 7.2.1.4. Others
  • 7.3. Latin America Nocturia Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospital Pharmacies
      • 7.3.1.2. Retail Pharmacies
      • 7.3.1.3. Drug Stores
      • 7.3.1.4. Online Pharmacies
  • 7.4. Latin America Nocturia Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Nocturia Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Nocturia Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Mixed nocturia
      • 8.1.1.2. Low nocturnal bladder capacity
      • 8.1.1.3. Nocturnal polyuria
      • 8.1.1.4. Global polyuria
  • 8.2. Middle East & Africa Nocturia Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Anticholinergic drugs
      • 8.2.1.2. Desmopressin
      • 8.2.1.3. Antispasmodic
      • 8.2.1.4. Others
  • 8.3. Middle East & Africa Nocturia Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospital Pharmacies
      • 8.3.1.2. Retail Pharmacies
      • 8.3.1.3. Drug Stores
      • 8.3.1.4. Online Pharmacies
  • 8.4. Middle East & Africa Nocturia Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Indication vs Distribution Channel Heatmap
  • 9.2. Manufacturer vs Distribution Channel Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Allergan, Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Indication Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Urigen Pharmaceuticals
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Indication Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Ferring Pharmaceuticals
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Indication Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Glenmark Pharmaceuticals Inc.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Indication Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Teva Pharmaceutical Industries Ltd.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Indication Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. AA Pharma Inc.
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Indication Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Avadel Pharmaceuticals plc
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Indication Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations